Rice Hydrolysate Formula in Infants and Children Allergic to Cow's Milk: A Systematic Review of Evidence.

IF 1.7 Q2 PEDIATRICS
Clinical Medicine Insights-Pediatrics Pub Date : 2025-06-05 eCollection Date: 2025-01-01 DOI:10.1177/11795565251332173
Khaled Saad, Amir Aboelgheet, Khalid Hashim, Eman F Gad, Anas Elgenidy, Ramez M Odat, Aya Sherif, Ahmed Altaweel, Asmaa B Zahran, Sara K Kamal, Abdelrahman Elshimy, Ahmed Samir, Anas Khaled, Ahmed Ibrahim, Amira Elhoufey, Hamad Ghaleb Dailah, Thamer Alruwaili, Hoda Atef Abdelsattar Ibrahim
{"title":"Rice Hydrolysate Formula in Infants and Children Allergic to Cow's Milk: A Systematic Review of Evidence.","authors":"Khaled Saad, Amir Aboelgheet, Khalid Hashim, Eman F Gad, Anas Elgenidy, Ramez M Odat, Aya Sherif, Ahmed Altaweel, Asmaa B Zahran, Sara K Kamal, Abdelrahman Elshimy, Ahmed Samir, Anas Khaled, Ahmed Ibrahim, Amira Elhoufey, Hamad Ghaleb Dailah, Thamer Alruwaili, Hoda Atef Abdelsattar Ibrahim","doi":"10.1177/11795565251332173","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Current guidelines recommend extensively hydrolyzed cow's milk protein formulas (EHF) as the first-line treatment for infants diagnosed with cow's milk allergy (CMA). Recently, rice hydrolysate formula (RHF) has emerged as a plant-based alternative with potential advantages in taste, cost-effectiveness, and safety.</p><p><strong>Objective: </strong>Our comprehensive systematic review aimed to evaluate the efficacy of RHF in managing CMA and assess the growth standards of children in short-term follow-up.</p><p><strong>Methods: </strong>We searched PubMed, Scopus, Cochrane, Embase, and Web of Science databases for relevant studies published until May 2024. Eligible studies were selected based on the inclusion criteria. Data extraction covered study characteristics, <i>Z</i>-scores (weight and length for age, weight for length, body mass index [BMI], and head circumference), tolerance, atopic manifestations, IgE levels, and symptoms-based score (SBS). Quality assessment was performed using appropriate tools for different study designs. Data analysis focused on identifying trends in growth parameters and tolerance outcomes among infants with CMA.</p><p><strong>Results: </strong>Seventeen studies, 1695 infants with CMA, and 145 healthy infants were included in the review. Weight-for-age <i>Z</i>-scores varied initially but showed improvement after the first month, except in 1 study. It showed a <i>Z</i> score decreased by an average of 0.69 from the baseline. Length-for-age <i>Z</i>-scores exhibited inconsistency, and RHF tended to have negative effects but performed better than the soy formula. Weight-for-length <i>Z</i>-scores indicated RHF as a reasonable alternative in the first 6 months. RHF gradually enhanced BMI over 6 months. Head circumference <i>Z</i>-scores varied, with RHF showing mixed results compared to cow's milk protein formula. Tolerance to RHF increased steadily over 2 years. Atopic manifestations at 36 months were moderate for RHF. IgE tests revealed similar sensitization rates across different formulas, and RHF showed effectiveness in symptom reduction over 6 months.</p><p><strong>Conclusion: </strong>This comprehensive review suggests that RHF can effectively substitute cow's milk formula in managing CMA. These formulas are well tolerated in infants, have varying impacts on growth development, and show promise in reducing atopic symptoms.</p>","PeriodicalId":45027,"journal":{"name":"Clinical Medicine Insights-Pediatrics","volume":"19 ","pages":"11795565251332173"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141802/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795565251332173","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Current guidelines recommend extensively hydrolyzed cow's milk protein formulas (EHF) as the first-line treatment for infants diagnosed with cow's milk allergy (CMA). Recently, rice hydrolysate formula (RHF) has emerged as a plant-based alternative with potential advantages in taste, cost-effectiveness, and safety.

Objective: Our comprehensive systematic review aimed to evaluate the efficacy of RHF in managing CMA and assess the growth standards of children in short-term follow-up.

Methods: We searched PubMed, Scopus, Cochrane, Embase, and Web of Science databases for relevant studies published until May 2024. Eligible studies were selected based on the inclusion criteria. Data extraction covered study characteristics, Z-scores (weight and length for age, weight for length, body mass index [BMI], and head circumference), tolerance, atopic manifestations, IgE levels, and symptoms-based score (SBS). Quality assessment was performed using appropriate tools for different study designs. Data analysis focused on identifying trends in growth parameters and tolerance outcomes among infants with CMA.

Results: Seventeen studies, 1695 infants with CMA, and 145 healthy infants were included in the review. Weight-for-age Z-scores varied initially but showed improvement after the first month, except in 1 study. It showed a Z score decreased by an average of 0.69 from the baseline. Length-for-age Z-scores exhibited inconsistency, and RHF tended to have negative effects but performed better than the soy formula. Weight-for-length Z-scores indicated RHF as a reasonable alternative in the first 6 months. RHF gradually enhanced BMI over 6 months. Head circumference Z-scores varied, with RHF showing mixed results compared to cow's milk protein formula. Tolerance to RHF increased steadily over 2 years. Atopic manifestations at 36 months were moderate for RHF. IgE tests revealed similar sensitization rates across different formulas, and RHF showed effectiveness in symptom reduction over 6 months.

Conclusion: This comprehensive review suggests that RHF can effectively substitute cow's milk formula in managing CMA. These formulas are well tolerated in infants, have varying impacts on growth development, and show promise in reducing atopic symptoms.

对牛奶过敏的婴儿和儿童的大米水解配方:证据的系统评价。
背景:目前的指南推荐广泛水解牛奶蛋白配方(EHF)作为诊断为牛奶过敏(CMA)的婴儿的一线治疗。最近,大米水解物配方(RHF)作为一种基于植物的替代品,在口感、成本效益和安全性方面具有潜在的优势。目的:评价RHF治疗CMA的疗效,评估短期随访儿童的生长标准。方法:检索PubMed、Scopus、Cochrane、Embase和Web of Science数据库,检索截止到2024年5月发表的相关研究。根据纳入标准选择符合条件的研究。数据提取包括研究特征、z评分(年龄的体重和身高、身高的体重、身体质量指数[BMI]和头围)、耐受性、特应性表现、IgE水平和基于症状的评分(SBS)。采用适当的工具对不同的研究设计进行质量评估。数据分析的重点是确定CMA婴儿的生长参数和耐受性结局的趋势。结果:17项研究,1695名CMA婴儿和145名健康婴儿被纳入本综述。体重与年龄比值的z分数在最初有所不同,但在第一个月后有所改善,只有一项研究例外。它显示Z分数比基线平均下降了0.69。长度与年龄的z分数表现出不一致性,RHF倾向于产生负面影响,但表现优于大豆配方。体重-长度z评分显示RHF在前6个月是一个合理的选择。RHF在6个月内逐渐提高BMI。头围z分数各不相同,与牛奶蛋白配方相比,RHF的结果好坏参半。对RHF的耐受性在2年内稳步增加。36个月时RHF的特应性表现为中度。IgE测试显示不同配方的致敏率相似,RHF在6个月内表现出症状减轻的有效性。结论:RHF可有效替代牛奶配方治疗CMA。这些配方在婴儿中耐受性良好,对生长发育有不同的影响,并显示出减少特应性症状的希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
5
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信